Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Wuhan Createrna Science And Technology Co. Ltd. is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 3 pending office actions are distributed among 3 distinct examiners, requiring the applicant to address three different individual perspectives. This distribution ensures that no single examiner has a majority influence over the current pending workload.
The prosecution activity is situated within 2 distinct art units, suggesting some technical overlap despite the involvement of 3 distinct examiners. ONDACHI, PAULINE WANJIKU MUCH is the busiest examiner for this portfolio, currently overseeing 1 busiest examiner pending office action. This examiner is one of the three individuals responsible for the 3 pending office actions currently active for the company.
For a practitioner, the presence of 2 distinct art units for 3 pending office actions indicates a relatively concentrated technical focus. However, the use of 3 distinct examiners means that strategies must be tailored to each individual, including ONDACHI, PAULINE WANJIKU MUCH. Monitoring these 3 pending office actions involves tracking progress across two different administrative units within the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ONDACHI, PAULINE WANJIKU MUCH | 1 | 100.0% | +0.0% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
| SCHMITT, MICHAEL J | 1 | 57.0% | +20.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18840250 | USE OF INDAZOLE COMPOUND FOR TREATING PSORIASIS | ONDACHI, PAULINE WANJIKU MUCH | — |
| 18833704 | COMPOUND SERVING AS MASP-2 INHIBITOR, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF | WHITE, DAWANNA SHAR-DAY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18833704 | COMPOUND SERVING AS MASP-2 INHIBITOR, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF | WHITE, DAWANNA SHAR-DAY | — |
| 18728496 | SALT OF ROCK INHIBITOR, CRYSTAL FORM OF SALT, COMPOSITION, AND PHARMACEUTICAL USE | SCHMITT, MICHAEL J | — |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18840250 | USE OF INDAZOLE COMPOUND FOR TREATING PSORIASIS | ONDACHI, PAULINE WANJIKU MUCH | 1627 | §101§102§103§112DP | Non-Final OA | — | Pending | Aug 21, 2024 |
| 18833704 | COMPOUND SERVING AS MASP-2 INHIBITOR, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF | WHITE, DAWANNA SHAR-DAY | 1627 | §103§112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18728496 | SALT OF ROCK INHIBITOR, CRYSTAL FORM OF SALT, COMPOSITION, AND PHARMACEUTICAL USE | SCHMITT, MICHAEL J | 1629 | §112DP | Non-Final OA | — | Pending | Jul 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWuhan Createrna Science And Technology Co. Ltd. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Pauline Wanjiku Much Ondachi has the most, with 1 of Wuhan Createrna Science And Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
